LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address a complex and untapped segment, childhood brain cancer. Due to the challenges in addressing this unmet need, including significant hurdles in enrolling patients for a clinical trial, there is a vacuum of options for those served with this diagnosis. As Kazia is working to pioneer this sub-segment, leveraging its network, in this note we examine the science and attempt to connect the dots on the potential market opportunity and dynamics despite the limited data points to date.
Our NPV valuation of US$294m or US$22.28 per basic ADR remains unchanged. Kazia reported net cash of US$11.0m (A$15.2m) at the end of December (2021), which we estimate will fund the company into H123 (H2 CY22). We expect the company will need to seek roughly US$51m in financing (including US$22m in FY23 and US$22m in FY24). Kazia established a US$35m at-the-market program in April 2022, which may fulfil a portion of our projected funding needs. The company had gross cash of A$6.958m at 31 March and in its 4C quarterly statement management reported a Q322 operating cash burn rate of A$6.5m.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Soo Romanoff +44 (0)20 3077 5700 healthcare@edisongroup.com
Harry Shrives +44 (0)20 3077 5700 healthcare@edisongroup.com
Learn more atwww.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/702815/Kazia-Therapeutics-KZIA-Deep-Dive-Into-Childhood-Brain-Cancer
